1-7 of 7
Giampaolo Bianchini
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer

Matteo Dugo, Chiun-Sheng Huang, Daniel Egle, Begoña Bermejo, Claudio Zamagni, Robert S. Seitz, Tyler J. Nielsen, Marc Thill, Antonio Antón-Torres, Stefania Russo, Eva Maria Ciruelos, Brock L. Schweitzer, Douglas T. Ross, Barbara Galbardi, Richard Greil, Vladimir Semiglazov, Balázs Gyorffy, Marco Colleoni, Catherine M. Kelly, Gabriella Mariani, Lucia Del Mastro, Olivia Blasi, Maurizio Callari, Lajos Pusztai, Pinuccia Valagussa, Giuseppe Viale, Luca Gianni, Giampaolo Bianchini
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (21): 4900–4909.
https://doi.org/10.1158/1078-0432.CCR-24-0149
Published: 01 November 2024
View articletitled, The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
Open the PDF for The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Modulation of the Estrogen/erbB2 Receptors Cross-talk by CDK4/6 Inhibition Triggers Sustained Senescence in Estrogen Receptor– and ErbB2-positive Breast Cancer

Lucia Viganò, Alberta Locatelli, Adele Ulisse, Barbara Galbardi, Matteo Dugo, Diego Tosi, Carlo Tacchetti, Tiziana Daniele, Balázs Győrffy, Lorenzo Sica, Marina Macchini, Milvia Zambetti, Stefania Zambelli, Giampaolo Bianchini, Luca Gianni
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (10): 2167–2179.
https://doi.org/10.1158/1078-0432.CCR-21-3185
Published: 13 May 2022
View articletitled, Modulation of the Estrogen/erbB2 Receptors Cross-talk by CDK4/6 Inhibition Triggers Sustained Senescence in Estrogen Receptor– and ErbB2-positive Breast Cancer
Open the PDF for Modulation of the Estrogen/erbB2 Receptors Cross-talk by CDK4/6 Inhibition Triggers Sustained Senescence in Estrogen Receptor– and ErbB2-positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer

Cristina Guardia, Giampaolo Bianchini, Oriol Arpí-LLucià, Silvia Menendez, David Casadevall, Barbara Galbardi, Matteo Dugo, Sonia Servitja, Juan Carlos Montero, Luis Soria-Jiménez, MohammadA Sabbaghi, Raul Peña, Juan Madoz-Gúrpide, Belen Lloveras, Ana Lluch, Pilar Eroles, Joaquin Arribas, Atanasio Pandiella, Luca Gianni, Federico Rojo, Ana Rovira, Joan Albanell
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (18): 5096–5108.
https://doi.org/10.1158/1078-0432.CCR-20-2915
Published: 15 September 2021
View articletitled, Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer
Open the PDF for Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

New Strategies in Breast Cancer: Immunotherapy

Lajos Pusztai, Thomas Karn, Anton Safonov, Maysa M. Abu-Khalaf, Giampaolo Bianchini
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (9): 2105–2110.
https://doi.org/10.1158/1078-0432.CCR-15-1315
Published: 01 May 2016
View articletitled, New Strategies in Breast Cancer: Immunotherapy
Open the PDF for New Strategies in Breast Cancer: Immunotherapy in another window
Journal Articles

Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer

Maurizio Callari, Vera Cappelletti, Francesca D'Aiuto, Valeria Musella, Antonio Lembo, Fabien Petel, Thomas Karn, Takayuki Iwamoto, Paolo Provero, Maria Grazia Daidone, Luca Gianni, Giampaolo Bianchini
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (2): 337–345.
https://doi.org/10.1158/1078-0432.CCR-15-0757
Published: 14 January 2016
View articletitled, Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer
Open the PDF for Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

Aleix Prat, Giampaolo Bianchini, Marlene Thomas, Anton Belousov, Maggie C.U. Cheang, Astrid Koehler, Patricia Gómez, Vladimir Semiglazov, Wolfgang Eiermann, Sergei Tjulandin, Mikhail Byakhow, Begoña Bermejo, Milvia Zambetti, Federico Vazquez, Luca Gianni, José Baselga
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (2): 511–521.
https://doi.org/10.1158/1078-0432.CCR-13-0239
Published: 16 January 2014
View articletitled, Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study
Open the PDF for Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study in another window
Includes: Supplementary data
Journal Articles

Distinct p53 Gene Signatures Are Needed to Predict Prognosis and Response to Chemotherapy in ER-Positive and ER-Negative Breast Cancers

Charles Coutant, Roman Rouzier, Yuan Qi, Jacqueline Lehmann-Che, Giampaolo Bianchini, Takayuki Iwamoto, Gabriel N. Hortobagyi, W. Fraser Symmans, Serge Uzan, Fabrice Andre, Hugues de Thé, Lajos Pusztai
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (8): 2591–2601.
https://doi.org/10.1158/1078-0432.CCR-10-1045
Published: 14 April 2011
View articletitled, Distinct p53 Gene Signatures Are Needed to Predict Prognosis and Response to Chemotherapy in ER-Positive and ER-Negative Breast Cancers
Open the PDF for Distinct p53 Gene Signatures Are Needed to Predict Prognosis and Response to Chemotherapy in ER-Positive and ER-Negative Breast Cancers in another window
Includes: Supplementary data